Skip to main content

Table 2 Results of KRAS testing by five CLIA-certified laboratories

From: Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories

Sample ID

Clinical Result*

Sequencing Lab 1

Sequencing Lab 2

Sequencing Lab 3

Primer Extension

Lab 4

Real-time PCR

Lab 5

1

WT**

WT

WT

WT

WT

WT

2

WT

WT

WT

WT

WT

WT

3

WT

WT

WT

WT

WT

WT

4

WT

WT

WT

WT

WT

WT

5

WT

WT

WT

WT

WT

WT

6

WT

WT

G12D

G12D

WT

WT

7

G12V

G12V

G12V

G12V

G12V

G12V

8

G12D

G12D

G12D

G12D

G12D

G12D

9

G12V

G12V

G12V

G12V

G12V

G12V

10

G12S

G12S

G12S

G12S

G12S

G12S

11

G12V

G12V

G12V

G12V

G12V

G12V

12

G12C

G12C

G12C

G12C

G12C

G12C

13

G12V

G12V

G12V

G12V

G12V

G12V

14

G12D

WT†

G12D

G12D

G12D

G12D

15

G13D

G13D

G13D

G13D

G13D

G13D

16

G13D

G13D

G13D

G13D

G13D

G13D

17

G13D

G13D

G13D

G13D

G13D

G13D

18

G13D

G13D

G13D

G13D

G13D

G13D

19

G13D

G13D

G13D

G13D

G13D

G13D

20

G13D

G13D

G13D

G13D

G13D

G13D

  1. *Samples were selected for testing based on these prior clinical results.
  2. **WT: wildtype; G12D: p.Gly12Asp; G12V: p.Gly12Val; G12S: p.Gly12Ser;
  3. G13D: p.Gly13Asp.
  4. †This laboratory did see some evidence that the sample had a mutation, but was below the confidence threshold. This specimen showed tumor enrichment of approximately 40%, which is at the lower level of detection for this laboratory.